Petros Pharmaceuticals receives FDA positive feedback on tech for OTC erectile dysfunction.

Petros Pharmaceuticals receives FDA positive feedback on self-selection tech for STENDRA, an erectile dysfunction drug, as it aims for OTC status. The FDA acknowledges the technology addresses concerns, particularly for nitrate-using patients. Petros plans to develop a Drug Facts Label and continue OTC STENDRA development, potentially becoming the first erectile dysfunction drug with OTC access.

April 16, 2024
4 Articles

Further Reading